Once adjusted for tumour size, nodal spread, grade, age, and HER2 status, there was evidence of a borderline difference in survival after chemotherapy in ER+ ILC vs. ER+ IDC (HR: 1.30, 95% CI: 1.00, 1.70) (Table 4). Here, ERBB2 is linked to neoplasm.